Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 10/20 | 0.55 |
| ▸ | PPARA | Q07869 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893515 | 0.97 | KDM4E (0.70) | KDM4EHPGDPPARGPPARALMNA | |
| SCHEMBL31095027 | 0.91 | KDM4E (0.60) | KDM4EHPGDPPARGPPARALMNA | |
| SCHEMBL821081 | 0.89 | KDM4E (0.57) | KDM4EHPGDLMNATARBP2TP53 | |
| SCHEMBL6437060 | 0.87 | KDM4E (0.72) | KDM4EHPGDPPARGPPARALMNA | |
| SCHEMBL7922595 | 0.87 | KDM4E (0.56) | KDM4EHPGDPPARGPPARALMNA | |
| SCHEMBL7906307 | 0.87 | KDM4E (0.56) | KDM4EHPGDPPARGPPARALMNA | |
| SCHEMBL10652783 | 0.86 | HSD17B10 (0.61) | KDM4EHPGDPPARGPPARALMNA | |
| SCHEMBL6505735 | 0.86 | KDM4E (0.55) | KDM4EPPARGPPARALMNAPPARD | |
| SCHEMBL31094991 | 0.86 | KDM4E (0.55) | KDM4EHPGDPPARGPPARALMNA | |
| SCHEMBL5215068 | 0.86 | TARBP2 (0.55) | KDM4EHPGDPPARGPPARALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1231482-C | Process for preparing thiazolidinedione derivatives and intermediates | HOFFMANN LA ROCHE (CH) | 2005-12-14 | — | — | CN | claimed |
| EP-1282619-B1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | claimed |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2004-02-05 | — | — | US | claimed |
| CN-1422267-A | Processes for the preparation of thiazolidinedione derivatives and intermediates | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | CN | claimed |
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2003-05-15 | — | — | US | claimed |
| EP-1282619-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | claimed |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | HOFFMANN-LA ROCHE INC. | 2001-12-06 | — | — | US | claimed |
| WO-2001079202-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-25 | — | — | WO | claimed |
| US-20240270731-A1 | DEUTERATED COMPOUNDS | ALEBUND PHARMACEUTICALS (HONG KONG) LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-116848095-B | Deuterated compounds | 礼邦生物医药(江苏)有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-116848095-A | Deuterated compounds | 礼邦医药(香港)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023016440-A1 | DEUTERATED COMPOUNDS | ALEBUND PHARMACEUTICALS (HONG KONG) LIMITED (CN) | 2023-02-16 | — | — | WO | disclosed |
| EP-1757596-B1 | TYROSINE DERIVATIVES SUBSTITUTED BY N-PHENYLACRYLOYL AS AGONISTS OF HPPAR ALPHA AND HPPAR GAMA | BEIJING MOLECULE SCIENCE AND T (CN) | 2010-09-29 | — | — | EP | disclosed |
| EP-1757596-B1 | TYROSINE DERIVATIVES SUBSTITUTED BY N-PHENYLACRYLOYL AS AGONISTS OF HPPAR ALPHA AND HPPAR GAMA | BEIJING MOLECULE SCIENCE AND T (CN) | 2010-09-29 | — | — | EP | disclosed |
| US-5330998-A | Anticholesterol agents | PFIZER INC. (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0389699-B1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER (US) | 1994-05-11 | — | — | EP | disclosed |
| EP-0389699-A1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0177353-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4725610-A | TREATMENT OF HYPERLIPEMIA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0177353-A2 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | KDM4E 1998/4885HPGD 763/4885PPARG 80/4885 |
| US-20240270731-A1 | DEUTERATED COMPOUNDS | CYP2D6, CYP11B2, DHCR7 | KDM4E 4082/4885HPGD 142/4885PPARG 451/4885 |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | KDM4E 1998/4885HPGD 763/4885PPARG 80/4885 |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | KDM4E 1998/4885HPGD 763/4885PPARG 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.